Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease

Mounting evidence indicates that sclerostin, a well-known inhibitor of bone formation, may qualify as a clinically relevant biomarker of chronic kidney disease-related mineral and bone disorder (CKD-MBD), including abnormal mineral and bone metabolism and extraskeletal calcification. For this purpos...

Descripción completa

Detalles Bibliográficos
Autores principales: De Maré, Annelies, Verhulst, Anja, Cavalier, Etienne, Delanaye, Pierre, Behets, Geert J., Meijers, Bjorn, Kuypers, Dirk, D’Haese, Patrick C., Evenepoel, Pieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947521/
https://www.ncbi.nlm.nih.gov/pubmed/31756992
http://dx.doi.org/10.3390/jcm8122027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947521/
https://www.ncbi.nlm.nih.gov/pubmed/31756992
http://dx.doi.org/10.3390/jcm8122027

Ejemplares similares